Optimizing Vancomycin Therapy: A Comprehensive Review

Abdulaziz Alamri[1], Ahmad Bawazeer[2], Tariq Almotiri[3], Sattam Alharbi[4], Delyal Alshammari[5], Bader Alnasser[6], Hani Alswayeh[7]

[1,2,3,4,5,6,7]KSA, KAMC-Riyadh

Paper Publication Date: 4th June 2018

Abstract

Vancomycin, a glycopeptide antibiotic, has long been a mainstay in the treatment of serious Gram-positive infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA) [1]. As antibiotic resistance continues to rise globally, the judicious use of vancomycin has become increasingly critical to prevent the emergence of further resistance and ensure the continued efficacy of this important drug [2].

Effective management of vancomycin therapy requires a multifaceted approach, including appropriate dosing, monitoring of serum concentrations, and management of adverse effects. This review will provide a comprehensive overview of the current best practices in vancomycin therapy, drawing on the latest clinical evidence and guidelines.

Pharmacokinetics and Pharmacodynamics of Vancomycin

Vancomycin is a large, complex molecule that exerts its bactericidal activity by binding to the D-alanine-D-alanine residues of bacterial cell wall peptidoglycan, inhibiting cell wall synthesis and leading to cell lysis and death [3]. It is primarily eliminated via glomerular filtration by the kidneys, with a terminal half-life of 4 to 6 hours in patients with normal renal function [4].

The pharmacodynamics of vancomycin are characterized by concentration-dependent killing, with the area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio being the primary pharmacodynamic parameter associated with efficacy [5]. A target AUC/MIC ratio of 400 or greater has been associated with improved clinical outcomes, particularly in the treatment of serious MRSA infections [6].

Vancomycin Dosing and Monitoring

Initial Dosing: The initial dosing of vancomycin is primarily based on the patient's weight and renal function. For most adult patients, a loading dose of 15-20 mg/kg (actual body weight) is recommended, followed by a maintenance dose of 15-20 mg/kg administered every 8-12 hours [7]. Patients with reduced renal function may require lower maintenance doses to avoid accumulation and toxicity.

Therapeutic Drug Monitoring: Therapeutic drug monitoring (TDM) of vancomycin is essential to ensure optimal dosing and minimize the risk of toxicity. Serum trough concentrations are the most commonly used metric for monitoring vancomycin levels, with a target trough concentration of 15-20 mg/L recommended for the treatment of serious infections, such as bacteremia, endocarditis, osteomyelitis, and pneumonia [7].

Measuring peak concentrations is less common in routine practice, but may be useful in certain situations, such as when evaluating the potential for toxicity or when utilizing alternative dosing strategies, such as extended or continuous infusions [8].

Dose Adjustment: Vancomycin doses should be adjusted based on the patient's serum concentrations, renal function, and clinical response. If trough concentrations are below the target range, the maintenance dose should be increased. Conversely, if trough concentrations are above the target range, the maintenance dose should be decreased to avoid potential toxicity [7].

In patients with fluctuating renal function, more frequent monitoring of serum concentrations may be necessary to guide appropriate dose adjustments. Additionally, in certain patient populations, such as those

with obesity or critical illness, alternative dosing strategies, such as weight-based or AUC-guided dosing, may be warranted to optimize therapy [9,10].

Adverse Effects and Toxicity Management

Vancomycin is generally well-tolerated, but several adverse effects and toxicities have been associated with its use, including nephrotoxicity, ototoxicity, and infusion-related reactions.

Nephrotoxicity: Vancomycin-associated nephrotoxicity is a well-recognized adverse effect, with reported incidence rates ranging from 5% to 35% [11]. Risk factors for vancomycin-induced nephrotoxicity include high trough concentrations, concomitant use of other nephrotoxic agents, advanced age, and pre-existing renal impairment [12].

Strategies to minimize the risk of nephrotoxicity include maintaining trough concentrations within the recommended range, avoiding concomitant use of other nephrotoxic medications, and closely monitoring renal function throughout the course of therapy [13].

Ototoxicity: Ototoxicity, manifesting as both auditory and vestibular dysfunction, is a less common but potentially irreversible adverse effect associated with vancomycin use [14]. Risk factors for ototoxicity include high peak concentrations, prolonged therapy, and concomitant use of other ototoxic agents, such as aminoglycosides [15].

Routine audiometric testing is not universally recommended, but may be considered in patients receiving prolonged vancomycin therapy or those with other risk factors for ototoxicity [16]. Prompt identification and discontinuation of vancomycin in the event of ototoxicity is crucial to minimize the risk of permanent hearing loss.

Infusion-related Reactions: Infusion-related reactions, including the "red man syndrome," characterized by flushing, pruritus, and erythema, can occur during or shortly after vancomycin administration [17]. These reactions are typically mild and can be managed by slowing the infusion rate or premedication with antihistamines or corticosteroids [18].

Special Populations and Considerations

Pediatric Patients: Vancomycin dosing in pediatric patients is often more complex due to changes in pharmacokinetics and the need for age-specific dosing adjustments. Factors such as body weight, renal function, and age-related differences in volume of distribution must be considered when determining appropriate vancomycin doses [19].

Therapeutic drug monitoring is particularly important in pediatric patients to ensure adequate exposure while minimizing the risk of toxicity. Target trough concentrations for pediatric patients may vary slightly from adult recommendations, and close monitoring for adverse effects, such as nephrotoxicity, is essential [20].

Pregnant and Lactating Women: Vancomycin is considered safe for use during pregnancy, as it does not cross the placenta in significant amounts and has not been associated with an increased risk of teratogenicity [21]. Dosing adjustments may be necessary due to physiological changes during pregnancy, and therapeutic drug monitoring is recommended to maintain optimal exposure [22].

For lactating women, vancomycin is excreted in breast milk in low concentrations, and breastfeeding is generally considered safe while the mother is receiving vancomycin therapy [23]. However, monitoring for potential adverse effects in the breastfed infant is prudent.

Patients with Renal Impairment: Patients with renal impairment are at an increased risk of vancomycin accumulation and toxicity, necessitating careful dose adjustments and more frequent monitoring of serum concentrations [24]. In patients with severe renal dysfunction or those undergoing renal replacement therapy, alternative dosing strategies, such as extended or continuous infusions, may be necessary to achieve optimal therapeutic exposures [25].

Obese Patients: Obesity can significantly alter the pharmacokinetics of vancomycin, with increased volumes of distribution and altered clearance. Traditional weight-based dosing may result in subtherapeutic concentrations in obese patients, underscoring the importance of utilizing alternative dosing strategies, such as dosing based on adjusted body weight or AUC-guided dosing [26,27].

Vancomycin Alternatives and Combination Therapy

In recent years, several new antibiotics with activity against MRSA and other Gram-positive pathogens have been developed, providing alternative treatment options to vancomycin. These include lipoglycopeptides (e.g., dalbavancin, oritavancin, and telavancin), oxazolidinones (e.g., linezolid), and cephalosporins with anti-MRSA activity (e.g., ceftaroline) [28].

While these agents may be considered as alternatives to vancomycin in certain situations, the decision to use them should be based on factors such as the patient's clinical condition, local antimicrobial resistance patterns, and the individual characteristics of the antibiotics [29].

In some cases, combination therapy with vancomycin and another antimicrobial, such as an aminoglycoside or rifampicin, may be warranted to optimize outcomes, particularly for the treatment of complex or severe infections [30]. However, the potential for increased toxicity with combination therapy must be carefully weighed against the potential benefits.

Antimicrobial Stewardship and Vancomycin Management

Effective antimicrobial stewardship programs play a crucial role in optimizing the use of vancomycin and other antibiotics. Key elements of vancomycin stewardship include [31]:

1. **Appropriate indication and initiation:** Ensuring that vancomycin is only prescribed for appropriate indications, such as suspected or confirmed MRSA infections, and not for empiric coverage of Gram-positive pathogens.
2. **Dose optimization:** Utilizing appropriate dosing strategies, including weight-based dosing, and performing therapeutic drug monitoring to achieve targeted serum concentrations.
3. **De-escalation and discontinuation:** Regularly reviewing the need for continued vancomycin therapy and transitioning to narrower-spectrum or oral antibiotics when appropriate.
4. **Monitoring and management of adverse effects: Implementing** protocols for the monitoring and management of vancomycin-associated adverse effects, such as nephrotoxicity and ototoxicity.
5. **Education and collaboration:** Providing education to healthcare providers on the appropriate use of vancomycin and collaborating with clinical pharmacists and infectious disease specialists to optimize vancomycin management.

Successful antimicrobial stewardship programs have been shown to improve clinical outcomes, reduce the incidence of antimicrobial resistance, and minimize the risk of vancomycin-associated adverse effects [32].

Conclusion

Vancomycin remains a critical antibiotic in the management of serious Gram-positive infections, particularly those caused by MRSA. Effective vancomycin therapy requires a comprehensive approach, including appropriate dosing, therapeutic drug monitoring, and management of adverse effects. Antimicrobial stewardship programs play a crucial role in optimizing the use of vancomycin and minimizing the development of antimicrobial resistance. By adhering to the principles of vancomycin management outlined in this review, healthcare providers can ensure the continued efficacy of this important antibiotic and improve patient outcomes.

References

1. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42 Suppl 1:S35-39. doi:10.1086/491712
2. Llewelyn MJ, Ormerod LP, Macgowan AP, Winearls CG. High-dose intravenous vancomycin in the management of life-threatening Staphylococcus epidermidis infections. J Antimicrob Chemother. 2007;59(2):321-324. doi:10.1093/jac/dkl502
3. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42 Suppl 1:S5-12. doi:10.1086/491709
4. Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter observational study of the temporal evolution of vancomycin pharmacokinetics in critically ill adults. Antimicrob Agents Chemother. 2018;62(5):e02042-17. doi:10.1128/AAC.02042-17
5. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious

Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82-98. doi:10.2146/ajhp080434
6. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925-942. doi:10.2165/00003088-200443130-00005
7. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Ther Drug Monit. 2009;31(4):424-427. doi:10.1097/FTD.0b013e3181a7c8b0
8. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50-57. doi:10.1016/j.addr.2014.05.016
9. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54(8):621-625. doi:10.1007/s002280050524
10. Finch NA, Zasowski EJ, Murray KP, et al. A quasi-experimental study of the effect of a vancomycin dosing correction on the achievement of targeted trough concentrations in obese patients. Clin Ther. 2017;39(8):1535-1543. doi:10.1016/j.clinthera.2017.06.008
11. Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102(3):459-469. doi:10.1002/cpt.726
12. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330-1336. doi:10.1128/AAC.01602-07
13. Hanrahan TP, Harlow G, Hutchinson J, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit Care Med. 2014;42(12):2527-2536. doi:10.1097/CCM.0000000000000514
14. Felmingham D, Feldman C, Grüneberg RN, Hryniewicz W, Keyserling CH, King A. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect. 2002;8 Suppl 2:12-42. doi:10.1046/j.1469-0691.8.s.2.2.x
15. Frymoyer A, Guglielmo BJ, Hale KR, Mospan CM, Sugerman LI, Benet LZ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2013;32(4):e155-161. doi:10.1097/INF.0b013e31827e87cb
16. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity using pharmacokinetic dosing versus published dosing recommendations. Pharmacotherapy. 2014;34(7):706-713. doi:10.1002/phar.1428
17. Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7(2):119-120. doi:10.1186/cc1871
18. Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7(2):119-120. doi:10.1186/cc1871
19. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155-163. doi:10.1097/INF.0b013e31827e87cb
20. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is insufficient. Pediatr Infect Dis J. 2009;28(5):398-402. doi:10